Activation of β2-adrenergic receptors hastens relaxation and mediates phosphorylation of phospholamban, troponin I, and C-protein in ventricular myocardium from patients with terminal heart failure

Circulation

Volumn 99, Issue 1, 1999, Pages 65-72

  Kaumann, Alberto ^a   Bartel, Sabine ^b   Molenaar, Peter ^c   Sanders, Louise ^a   Burrell, Kylie ^c   Vetter, Donathe ^b   Hempel, Petra ^b   Karczewski, Peter ^b   Krause, Ernst Georg ^b  

^a BABRAHAM INSTITUTE   (United Kingdom)

^b MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^c NONE

Author keywords

Catecholamines; Contractility, diastole; Heart failure; Phosphoproteins; Receptors, adrenergic, beta 2

Indexed keywords

3 ISOPROPYLAMINO 1 (7 METHYL 4 INDANYLOXY) 2 BUTANOL; 5 [2 [[2 HYDROXY 3 [4 (1 METHYL 4 TRIFLUOROMETHYL 2 IMIDAZOLYL)PHENOXY]PROPYL]AMINO]ETHOXY]SALICYLAMIDE; BETA ADRENERGIC RECEPTOR; PHOSPHOLAMBAN; PROTEIN C; TROPONIN I; ADRENALIN; BETA 2 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CALCIUM; CALCIUM BINDING PROTEIN; CARRIER PROTEIN; CITRATE BINDING TRANSPORT PROTEIN; CITRATE-BINDING TRANSPORT PROTEIN; NORADRENALIN; VASODILATOR AGENT;

ADOLESCENT; ADULT; ARTICLE; CATECHOLAMINE RELEASE; CLINICAL ARTICLE; DRUG EFFECT; ENZYME ACTIVITY; FEMALE; HEART FAILURE; HEART MUSCLE CONTRACTILITY; HUMAN; MALE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RECEPTOR AFFINITY; RECEPTOR BINDING; RECEPTOR UPREGULATION; SARCOPLASMIC RETICULUM; CLINICAL TRIAL; CONGESTIVE CARDIOMYOPATHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG POTENTIATION; HEART MUSCLE ISCHEMIA; HEART VENTRICLE; METABOLISM; METHODOLOGY; MIDDLE AGED; PHOSPHORYLATION; TERMINAL CARE;

ADOLESCENT; ADRENERGIC BETA-AGONISTS; ADULT; CALCIUM; CALCIUM-BINDING PROTEINS; CARDIOMYOPATHY, DILATED; CARRIER PROTEINS; EPINEPHRINE; FEMALE; HEART VENTRICLES; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; NOREPINEPHRINE; PHOSPHORYLATION; RECEPTORS, ADRENERGIC, BETA-2; TERMINAL CARE; TROPONIN I; VASODILATOR AGENTS;

EID: 0033547702     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.99.1.65     Document Type: Article

References (46)

1. Katz AM. Interplay between inotropic and lusitropic effects of cyclic adenosine monophosphate on the myocardial cell. Circulation. 1990; 82(suppl I):I-7-I-11.
2. Tada M, Kirchberger MA, Katz AM. Phosphorylation of a 22,000-Dalton component of the cardiac sarcoplasmic reticulum by adenosine 3′:5′-monophosphate-dependent protein kinase. J Biol Chem. 1975;250: 2640-2647.
3. Koss KL, Kranias EG. Phospholamban: a prominent regulator of myocardial contractility. Circ Res. 1996;79:1059-1063.
4. Solaro RJ, Moir AJG, Perry SV. Phosphorylation of troponin I and the inotropic effect of adrenaline in the perfused rabbit heart. Nature. 1976; 262:615-617.
5. Jeacocke SA, England PJ. Phosphorylation of a myofibrillar protein of Mr 150,000 in perfused rat heart, and the tentative identification of this as C-protein. FEBS Lett. 1980;122:129-132.
6. 2+ sensitive tension due to partial extraction of C-protein from rat skinned cardiac myocytes and rabbit skeletal muscle fibers. J Gen Physiol. 1991;97: 1141-1163.
7. Wegener AD, Simmerman HKB, Lindemann JP, Jones LR. Phospholamban phosphorylation in intact ventricles: phosphorylation of serine 16 and threonine 17 in response to β-adrenergic stimulation. J Biol Chem. 1989;64:11468-11474.
8. Ray KP, England PJ. Phosphorylation of the inhibitory subunit of troponin and its effect on the calcium dependence of cardiac myofibril adenosine triphosphatase. FEBS Lett. 1976;70:11-16.
9. Zhang R, Zhao J, Mandveno A, Potter JD. Cardiac troponin I phosphorylation increases the rate of cardiac muscle relaxation. Circ Res. 1995; 76:1028-1035.
10. Lorell BH. Significance of diastolic dysfunction of the heart. Annu Rev Med. 1991;42:411-436.
11. Grossman W. Diastolic dysfunction in congestive heart failure. N Engl J Med. 1991;325:1557-1564.
12. Gwathmey JK, Copelas L, MacKinnon R, Schoen FJ, Feldman MD, Grossman W, Morgan JP. Abnormal intracellular calcium handling in myocardium from patients with end-stage heart failure. Circ Res. 1987; 61:70-76.
13. Feldman MD, Copelas L, Gwathmey JK, Phillips P, Warren SE, Schoen FJ, Grossman W, Morgan JP. Deficient production of cyclic AMP: pharmacological evidence of an important cause of contractile dysfunction in patients with end-stage heart failure. Circulation. 1987;75: 331-339.
14. Bartel S, Stein B, Eschenhagen T, Mende U, Neumann J, Schmitz W, Krause E-G, Karczewski P, Scholz H. Protein phosphorylation in isolated trabeculae from nonfailing and failing hearts. Mol Cell Biochem. 1996; 157:171-179.
15. Parker JD, Landzberg JS, Bittl JA, Mirsky I, Colucci WS. Effects of β-adrenergic stimulation with dobutamine on isovolumic relaxation in the normal and failing human left ventricle. Circulation. 1991;84:1041-1048.
16. Ruffolo RR, Messick K, Horng JS. Interactions of three inotropic agents, ASL-7022, dobutamine and dopamine, with α-and β-adrenoceptors in vitro. Naunyn Schmiedebergs Arch Pharmacol. 1984;326:317-326.
17. Maccarrone C, Malta E, Raper C. β-Adrenoceptor selectivity of dobutamine: in vivo and in vitro studies. J Cardiovasc Pharmacol. 1984;6: 132-141.
18. 2-adrenoceptor-mediated positive inotropic effect possibly unrelated to cyclic AMP. Naunyn Schmiedebergs Arch Pharmacol. 1991;344:56-69.
19. 2-adrenoceptors in sheep cardiac ventricular muscle. J Mol Cell Cardiol. 1992;24:753-764.
20. 2+ current in single rat ventricular cells. Circ Res. 1993;73:286-300.
21. 2+ dynamics, contractility, or phospholamban phosphorylation. J Biol Chem. 1994;269:19151-19156.
22. 2-adrenoceptor to a pertussis toxin-sensitive G protein in cardiac myocytes. Mol Pharmacol. 1995;47:322-329.
23. 2-adrenergic stimulation. Circulation. 1995;92:1612-1618.
24. 2-adrenoceptors in human atrium. Circ Res. 1990;66: 1610-1623.
25. 2-adrenoceptor activation by zinterol causes protein phosphorylation, contractile effects and relaxant effects through a cAMP pathway in human atrium. Mol Cell Biochem. 1996;163/164:113-123.
26. 2-adrenoceptors in single myocytes from human ventricle. Circulation. 1993;88:889-893.
27. 2-Adrenoceptor-mediated positive inotropic effects of adrenaline in human ventricular myocardium: quantitative discrepancies between binding and adenylate cyclase stimulation. Naunyn Schmiedebergs Arch Pharmacol. 1987;335:403-411.
28. 2-adrenoceptors of human heart: differential antagonism of the positive inotropic effects and adenylate cyclase stimulation by (-)-noradrenaline and (-)-adrenaline. Naunyn Schmiedebergs Arch Pharmacol. 1985;331:60-70.
29. Karczweski P, Bartel S, Krause E-G. Differential sensitivity to isoproterenol of troponin I and phospholamban phosphorylation in isolated rat heart. Biochem J. 1990;266:115-122.
30. Lowry OH, Rosebrough NJ, Fair AL, Randall RJ. Protein measurement with Folin reagent. J Biol Chem. 1951;193:265-275.
31. Drago GA, Colyer J. Discrimination between two sites of phosphorylation on adjacent amino acids by phosphorylation site-specific antibodies to phospholamban. J Biol Chem. 1994;269:25073-25077.
32. Bristow MR, Hershberger RE, Port JD, Gilbert EM, Sandoval A, Rasmussen R, Cates AE, Feldman AM. β-Adrenergic pathways in nonfailing and failing human ventricular myocardium. Circulation. 1990;82(suppl I):I-12-I-25.
33. Tweedie D, O'Gara P, Harding SE, MacLeod KT. The effect of alterations to action potential duration on β-adrenoceptor-mediated aftercontractions in human and guinea-pig ventricular myocytes. J Mol Cell Cardiol. 1997;29:1457-1467.
34. Kaumann AJ, Lemoine H, Schwederski-Menke U, Ehle B. Relations between β-adrenoceptor occupancy and increases of contractile force and adenylate cyclase activity induced by catecholamines in human ventricular myocardium: acute desensitization and comparison with feline ventricle. Naunyn Schmiedebergs Arch Pharmacol. 1989;339:99-112.
35. 2-adrenergic receptor-mediated adenylate cyclase stimulation in non-failing and failing human ventricular myocardium. Mol Pharmacol. 1989; 35:295-303.
36. 2-adrenoceptors. Pharmacol Commun. 1995;6:215-222.
37. s. Mol Pharmacol. 1992;41:889-893.
38. 2-adrenergic receptors. Proc Natl Acad Sci USA. 1993;90:10798-10802.
39. Feldman AM, Cates AE, Veazey WB, Hershberger RE, Bristow MR, Baughman KL, Baumgartner WA, vanDop C. Increase in the 40,000-mol wt pertussis toxin substrate (G-protein) in the failing human heart. J Clin Invest. 1988;82:189-197.
40. i-proteins in human heart failure. Lancet. 1988;11:936-937.
41. iαa2 in human end-stage heart failure. Circ Res. 1992;70:688-696.
42. 2-adrenoceptors in human ventricular myocardium from failing hearts hastens the onset of relaxation. Br J Pharmacol. 1992;105:283P. Abstract.
43. ++ current in cardiac myocytes. J Pharmacol Exp Ther. 1997; 282:452-461.
44. Mundina-Weilenmann C, Vittone L, Ortale M, Chiappe de Cingolani G, Mattiazzi A. Immunodetection of phosphorylation sites gives new insights into the mechanisms underlying phospholamban phosphorylation in the intact heart. J Biol Chem. 1996;271:33561-33567.
45. Gupta RC, Neumann J, Watanabe AM, Lesch M, Sabbah HN. Evidence for presence and hormonal regulation of protein phosphatase inhibitor-1 in ventricular cardiomyocytes. Am J Phvsiol. 1996;270(Heart Circ Physiol 39):H1159-H1164.
46. Waagstein F, Bristow MR, Swedberg K, Camerini F, Fowler MB, Silver MA, Gilbert EM, Johnson MR, Gross FG, Hjalmarson A. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet. 1993;342:1441-1446.